0001558370-23-018912.txt : 20231114 0001558370-23-018912.hdr.sgml : 20231114 20231114073009 ACCESSION NUMBER: 0001558370-23-018912 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231114 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptimmune Therapeutics PLC CENTRAL INDEX KEY: 0001621227 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37368 FILM NUMBER: 231401583 BUSINESS ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX BUSINESS PHONE: 44 1235 430000 MAIL ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX FORMER COMPANY: FORMER CONFORMED NAME: Adaptimmune Ltd DATE OF NAME CHANGE: 20141001 8-K 1 adap-20231114x8k.htm 8-K
0001621227false00-000000000016212272023-11-142023-11-14

​

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 14, 2023

​

ADAPTIMMUNE THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

England and Wales

​

1-37368

​

Not Applicable

(State or other jurisdiction of
incorporation)

​

(Commission File Number)

​

(IRS Employer Identification No.)

​

60 Jubilee Avenue, Milton Park

Abingdon, Oxfordshire OX14 4RX

United Kingdom

(Address of principal executive offices, including zip code)

​

(44) 1235 430000

(Registrant’s telephone number, including area code)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

​

Trading Symbol

​

Name of each exchange on which
registered

American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share

​

ADAP

​

The Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

​

​

​

​

​

​

Item 8.01    Other Events.

Adaptimmune Therapeutics plc (the “Company”) is filing this Current Report on Form 8-K to amend Exhibit 23.1 (the “Original Exhibit 23.1”) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on March 6, 2023 (the “2022 Form 10-K”). The Company’s independent registered public accounting firm, KPMG LLP, consented to the use of their reports dated March 6, 2023 that are included in the 2022 Form 10-K. In the Original Exhibit 23.1, reference to our registration statement on Form S-3 (No. 333-264208) was inadvertently omitted. The revised consent attached hereto as Exhibit 23.1 (the “Revised Exhibit 23.1”) supersedes and replaces the Original Exhibit 23.1. The Revised Exhibit 23.1 does not change any previously reported financial results of operations or any other disclosure contained in the 2022 Form 10-K.

tem 9.01    Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit No.

    

Description of Exhibit

23.1

​

Consent of KPMG LLP

104

​

Cover Page Interactive Date File (embedded within the Inline XBRL document)

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

​

​

​

ADAPTIMMUNE THERAPEUTICS PLC

​

​

​

Date: November 14, 2023

By:

/s/ Margaret Henry

​

​

Name:

Margaret Henry

​

​

Title:

Corporate Secretary

​

​

 EX-23.1 2 adap-20231114xex23d1.htm EX-23.1

Exhibit 23.1

​

Consent of Independent Registered Public Accounting Firm

​

​

We consent to the incorporation by reference in the registration statements No.333-264208 on Form S-3 and Nos. 333-233558 and 333-203929 on Form S-8 of Adaptimmune Therapeutics plc of our reports dated March 6, 2023, with respect to the consolidated financial statements of Adaptimmune Therapeutics plc and the effectiveness of internal control over financial reporting which reports appear in the Form 10-K of Adaptimmune Therapeutics plc dated March 6, 2023.

​

/s/ KPMG LLP

Reading, United Kingdom

November 14, 2023

 EX-101.SCH 3 adap-20231114.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 adap-20231114_lab.xml EX-101.LAB EX-101.PRE 5 adap-20231114_pre.xml EX-101.PRE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 14, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 14, 2023
Entity File Number 1-37368
Entity Registrant Name ADAPTIMMUNE THERAPEUTICS PLC
Entity Incorporation, State or Country Code X0
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One 60 Jubilee Avenue
Entity Address, Adress Line Two Milton Park
Entity Address, City or Town Abingdon, Oxfordshire
Entity Address, Postal Zip Code OX14 4RX
Entity Address, Country GB
City Area Code 44
Local Phone Number 1235 430000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share
Trading Symbol ADAP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001621227
Amendment Flag false
XML 7 adap-20231114x8k_htm.xml IDEA: XBRL DOCUMENT 0001621227 2023-11-14 2023-11-14 0001621227 false 00-0000000 8-K 2023-11-14 ADAPTIMMUNE THERAPEUTICS PLC X0 1-37368 60 Jubilee Avenue Milton Park Abingdon, Oxfordshire OX14 4RX GB 44 1235 430000 false false false false American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share ADAP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adap-20231114.xsd adap-20231114_lab.xml adap-20231114_pre.xml adap-20231114x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "adap-20231114x8k.htm": { "nsprefix": "adap", "nsuri": "http://www.adaptimmune.com/20231114", "dts": { "schema": { "local": [ "adap-20231114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "adap-20231114_lab.xml" ] }, "presentationLink": { "local": [ "adap-20231114_pre.xml" ] }, "inline": { "local": [ "adap-20231114x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_11_14_2023_To_11_14_2023_tsefWRnd0kWFU4JB8bKyRA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adap-20231114x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_11_14_2023_To_11_14_2023_tsefWRnd0kWFU4JB8bKyRA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "adap-20231114x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "adap_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.adaptimmune.com/20231114", "localname": "DocumentAndEntityInformationAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001558370-23-018912-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-018912-xbrl.zip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end